Want to see TSE:DTC full AI Analyst Report?
DTC Stock Chart & Stats
C$0.78
-C$0.03(-4.41%)
At close: 4:00 PM EST
C$0.78
-C$0.03(-4.41%)
Day’s Range― - ―
52-Week RangeC$0.39 - C$0.93
Previous CloseN/A
Volume0.00
Average Volume (3M)68.27K
Market Cap
C$29.94M
Enterprise ValueC$31.08
Total Cash (Recent Filing)C$2.95M
Total Debt (Recent Filing)C$1.56M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Oct 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding75,788,155
10 Day Avg. Volume109,889
30 Day Avg. Volume68,269
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-27.77
Price to Sales (P/S)0.00
P/FCF Ratio-10.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform TechnologyDefence Therapeutics’ Accum® platform is a durable technological asset enabling intracellular delivery of biologics across oncology and infectious disease programs. A platform approach supports multiple programs, potential licensing or partnerships, and long-term optionality independent of any single asset.
Improving Loss TrajectoryA material reduction in net loss between 2024 and 2025 signals management cost control or program prioritization that can extend runway. Sustained improvement reduces near-term financing pressure and demonstrates operational adjustments that matter over the coming months.
Latest Positive Equity And Asset GrowthPositive shareholders’ equity and rising total assets provide a cleaner balance-sheet base versus prior years, offering a buffer for near-term obligations. This improved capital position enhances financial flexibility for R&D or strategic partnerships over the medium term.
Bears Say
No Revenue / Negative Gross ProfitThe absence of product revenue and negative gross profit mean the business cannot self-fund operations; success depends on clinical or tech validation events. This structural revenue gap keeps long-term viability contingent on R&D outcomes or external funding, raising execution risk.
Persistent Cash BurnSustained negative operating and free cash flow indicate ongoing cash consumption and the need for external capital. Continued burn elevates dilution and refinancing risk, constraining strategic choices and potentially delaying development timelines absent durable funding sources.
Very Small Team / Limited ScaleA five-person workforce limits in-house development, regulatory, and commercial capabilities, increasing reliance on partners, CROs, or hires. This structural constraint can slow program execution, raise outsourcing costs, and amplify operational risk over the next several months.
Defence Therapeutics News
DTC FAQ
What was Defence Therapeutics’s price range in the past 12 months?
Defence Therapeutics lowest stock price was C$0.39 and its highest was C$0.93 in the past 12 months.
What is Defence Therapeutics’s market cap?
Defence Therapeutics’s market cap is C$29.94M.
When is Defence Therapeutics’s upcoming earnings report date?
Defence Therapeutics’s upcoming earnings report date is Oct 28, 2026 which is in 97 days.
How were Defence Therapeutics’s earnings last quarter?
Defence Therapeutics released its earnings results on May 22, 2026. The company reported -C$0.05 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Defence Therapeutics overvalued?
According to Wall Street analysts Defence Therapeutics’s price is currently Overvalued.
Does Defence Therapeutics pay dividends?
Defence Therapeutics does not currently pay dividends.
What is Defence Therapeutics’s EPS estimate?
Defence Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Defence Therapeutics have?
Defence Therapeutics has 75,788,155 shares outstanding.
What happened to Defence Therapeutics’s price movement after its last earnings report?
Defence Therapeutics reported an EPS of -C$0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.263%.
Which hedge fund is a major shareholder of Defence Therapeutics?
Currently, no hedge funds are holding shares in TSE:DTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Defence Therapeutics
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its approach is the exclusive ACCUM™ technology, engineered to precisely and safely transport vaccine antigens or antibody-drug conjugates (ADCs) directly to their intended cellular targets. The company's development efforts span several key areas: novel dendritic cell vaccines for various cancers, protein-based vaccines addressing COVID-19 and other infectious ailments, and specialized antibody-drug conjugate products aimed at different cancer types. Defence Therapeutics Inc. adopted its current name in March 2020, having previously operated as Accum Therapeutics Inc.
Technical Analysis
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Onco-Innovations Ltd.
―